Disparition de kératoses actiniques avec la capécitabine = Resolution of actinic keratosis with capecetabinSCHMUTZ, J.-L; TRECHOT, P.Annales de dermatologie et de vénéréologie. 2012, Vol 139, Num 11, pp 759-760, issn 0151-9638, 2 p.Article

Capecitabine- induced multifocal leukoencephalopathy : A report of five casesVIDENOVIC, A; SEMENOV, I; RAIZER, J. J et al.Neurology. 2005, Vol 65, Num 11, pp 1792-1794, issn 0028-3878, 3 p.Article

Genital Erythrodysesthesia as a Severe Manifestation of Capecitabine Therapy: A Report of 3 CasesFLETA-ASIN, Beatriz; ALCANTARA-GONZALEZ, Javier; ALONSO-CASTRO, Leticia et al.Archives of dermatology (1960). 2011, Vol 147, Num 9, pp 1123-1124, issn 0003-987X, 2 p.Article

Resolving actinic keratoses: an expected side-effect of capecitabine therapyAL-NIAIMI, F; LYON, C.Clinical and experimental dermatology (Print). 2012, Vol 37, Num 1, pp 68-69, issn 0307-6938, 2 p.Article

Capecitabine-Induced Chest Pain Relieved by DiltiazemAMBROSY, Andrew P; KUNZ, Pamela L; FISHER, George A et al.The American journal of cardiology. 2012, Vol 110, Num 11, pp 1623-1626, issn 0002-9149, 4 p.Article

Capecitabine-induced coronary vasospasm: A case reportRIZVI, Asad A; SCHAUER, Peter; OWLIA, Dariush et al.Angiology. 2004, Vol 55, Num 1, pp 93-97, issn 0003-3197, 5 p.Article

Successful Treatment of HER-2-Positive Metastatic Apocrine Carcinoma of the Skin with Lapatinib and CapecitabineHIDAKA, Takanori; FUJIMURA, Taku; WATABE, Akiko et al.Acta dermato-venereologica. 2012, Vol 92, Num 6, pp 654-655, issn 0001-5555, 2 p.Article

Complete Response of Metastatic Malignant Hidradenocarcinoma to Capecitabine TreatmentLERNER, Adam; BECKFORD, Angela; UGENT, Steve et al.Archives of dermatology (1960). 2011, Vol 147, Num 8, pp 998-999, issn 0003-987X, 2 p.Article

Exudative, Nonhealing Scalp: A Complication of Systemic Chemotherapy With Capecitabine and BevacizumabBLACK, Jeanette M; HODARI, Kafele T; ROGERS, Nicole et al.Archives of dermatology (1960). 2011, Vol 147, Num 1, pp 134-135, issn 0003-987X, 2 p.Article

A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving CapecitabineHENIN, E; YOU, B; TOD, M et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 4, pp 418-425, issn 0009-9236, 8 p.Article

Focal Acral Hyperpigmentation in a Patient Undergoing Chemotherapy with CapecitabineVILLALON, Guillermo; MARTIN, Jose M; PINAZO, Maria I et al.American journal of clinical dermatology. 2009, Vol 10, Num 4, pp 261-263, issn 1175-0561, 3 p.Article

Toxicité sévère à la capécitabine liée à un déficit enzymatique en dihydropyrimidine déshydrogénase (DPD) = Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiencyCOURSIER, S; MARTELET, S; GUILLERMET, A et al.Gastroentérologie clinique et biologique. 2010, Vol 34, Num 3, pp 218-223, issn 0399-8320, 6 p.Article

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulationMILANO, G; FERRERO, J.-M; FRANCOIS, E et al.British journal of cancer. 2004, Vol 91, Num 4, pp 613-617, issn 0007-0920, 5 p.Article

Hyperpigmentation à la capecitabine suivie de syndrome mains-pieds: une nouvelle observation = Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: A new case reportAGHARBI, F.-Z; MEZIANE, M; BENHEMMNE, H et al.Annales de dermatologie et de vénéréologie. 2012, Vol 139, Num 3, pp 221-222, issn 0151-9638, 2 p.Article

A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinomaTURKINGTON, R. C; PURCELL, C; JAMES, C. R et al.Investigational new drugs. 2014, Vol 32, Num 2, pp 250-260, issn 0167-6997, 11 p.Article

A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinomaOGASAWARA, Sadahisa; CHIBA, Tetsuhiro; OOKA, Yoshihiko et al.Investigational new drugs. 2014, Vol 32, Num 4, pp 762-768, issn 0167-6997, 7 p.Article

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTereSOARES, Heloisa P; BAYRAKTAR, Soley; WALKER, Gail et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 4, pp 839-845, issn 0344-5704, 7 p.Article

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trialCHU, E; HALLER, D; CARTWRIGHT, T et al.British journal of cancer. 2014, Vol 110, Num 6, pp 1438-1445, issn 0007-0920, 8 p.Article

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II studyWATKINS, D. J; STARLING, N; CUNNINGHAM, D et al.European journal of cancer (1990). 2014, Vol 50, Num 8, pp 1422-1429, issn 0959-8049, 8 p.Article

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment optionMEULENDIJKS, D; DEWIT, L; TOMASOA, N. B et al.British journal of cancer. 2014, Vol 111, Num 9, pp 1726-1733, issn 0007-0920, 8 p.Article

Cost―Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric CancerTAN CHONGQING; PENG LIUBAO; ZENG XIAOHUI et al.PharmacoEconomics (Auckland). 2014, Vol 32, Num 3, pp 235-243, issn 1170-7690, 9 p.Article

Breast cancer drugs dampen vascular functions by interfering with nitric oxide signaling in endotheliumGAJALAKSHMI, Palanivel; KRISHNA PRIYA, Mani; PRADEEP, Thangaraj et al.Toxicology and applied pharmacology. 2013, Vol 269, Num 2, pp 121-131, issn 0041-008X, 11 p.Article

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104BOECK, S; JUNG, A; GAULER, T. C et al.British journal of cancer. 2013, Vol 108, Num 2, pp 469-476, issn 0007-0920, 8 p.Article

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)DUCREUX, M; ADENIS, A; CONROY, T et al.European journal of cancer (1990). 2013, Vol 49, Num 6, pp 1236-1245, issn 0959-8049, 10 p.Article

Fluorouracil in the environment: Analysis, occurrence, degradation and transformationKOSJEK, Tina; PERKO, Silva; ZIGON, Dusan et al.Journal of chromatography. 2013, Vol 1290, pp 62-72, issn 0021-9673, 11 p.Article